Breaking News

MolMed S.p.A Becomes AGC Biologics S.p.A

AGC Biologics now provides end-to-end cell and gene therapy CDMO services.

By: Contract Pharma

Contract Pharma Staff

After its parent company AGC Inc. acquired 100% of the shares of MolMed S.p.A. on September 30, 2020, AGC Biologics said that MolMed’s entity name has been changed to AGC Biologics S.p.A.   This Center of Excellence for AGC Biologics’ cell and gene therapy contract development and manufacturing organization (CDMO) services is in Milan, Italy. The Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has commercial manufacturing experience...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters